NRAS and neoplasm: Additionally, to investigate the prediction performance of those gene mutations before surgery (NRAS, MET, and NF2E2L2), we used machine learning methods to select predictive factors to predict early recurrence, which showed that the c‐index for median VAF of NRAS, NEF2L2, and MET mutations was 0.80 (Fig. S6A), while the c‐index for combined NRAS, NEF2L2, MET mutations, and clinical parameters (BCLC stage, tumor size, and MVI) was 0.97 (Table S1; Fig. S6B).